RECURRENT MALIGNANT GLIOMA
Clinical trials for RECURRENT MALIGNANT GLIOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT MALIGNANT GLIOMA trials appear
Sign up with your email to follow new studies for RECURRENT MALIGNANT GLIOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Promising targeted therapy for recurrent brain tumors in kids and young adults
Disease control Recruiting nowThis study is testing a drug called Lutathera in people aged 4 to 39 with certain aggressive brain tumors or meningiomas that have come back or are growing. The drug delivers radiation directly to tumor cells that show up on a special PET scan. The goal is to find the safest dose…
Matched conditions: RECURRENT MALIGNANT GLIOMA
Phase: PHASE1, PHASE2 • Sponsor: Nationwide Children's Hospital • Aim: Disease control
Last updated May 17, 2026 04:37 UTC
-
Engineered immune cells take on recurrent brain tumors in first human trial
Disease control Recruiting nowThis early-phase study tests a new treatment for people whose high-grade glioma (a type of brain cancer) has returned after previous therapy. The treatment uses the patient's own immune cells, which are modified in a lab to recognize and attack a protein called GARP found on tumo…
Matched conditions: RECURRENT MALIGNANT GLIOMA
Phase: PHASE1 • Sponsor: Ohio State University Comprehensive Cancer Center • Aim: Disease control
Last updated May 15, 2026 11:56 UTC
-
Cold virus turned against brain tumors in new trial
Disease control Recruiting nowThis early-phase trial tests a modified cold virus (DNX-2401) that targets and attacks brain cancer cells. The virus is loaded into donor stem cells and injected into an artery near the tumor. The study includes 36 adults with recurrent high-grade glioma and aims to find the safe…
Matched conditions: RECURRENT MALIGNANT GLIOMA
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 11, 2026 20:47 UTC